Current law blocks Medicare weight-loss drug coverage Policy changes expected mid-2026 Medicaid coverage remains state-dependent What This Means for You Coverage is stable: Wegovy's preferred status on Aetna expected to continue Focus on PA requirements: Meeting criteria is key to approval Cardiovascular benefit: Wegovy's heart health approval (March 2024) strengthens your case During open enrollment: Confirm no changes to your specific plan's requirements CALL YOUR INSURANCE Verify Your Specific Coverage Verify Your Specific Coverage Even though it takes a little more time, we recommend calling so you can speak with a person who may have more information than the online directory or PDF formulary listing
GLP-1s are game-changers if you've got significant weight to lose
In the Sema/HFD group, the most enriched GO terms of BP, MF, and CC were annotated as immune effector process, signaling receptor activity, and extracellular region part, respectively ( Figures 5C, D , Table 3 )
Timing changes should never coincide with dose changes
Clinical trials demonstrate that semaglutide reduces body weight by up to 22% in adults with obesity or overweight status
:max_bytes(150000):strip_icc()/Health-GettyImages-2153927815-0bf99cd73e2c46908d7fc0973739f6d0.jpg)
